ClinicalTrials.gg
TerminatedNCT05035576Updated May 2, 2022

A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19

A Phase 1 interventional study of OPN-019 in Covid19, sponsored by Optinose US Inc.. Terminated at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Optinose US Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in COVID-19 with a site in Mexico — 12 open to participants now, 14 under way, 6 of them phase 3. COVID-19 · Mexico.

Enrollment
143rd of 151
8 · median 200
Started
2021
with 56 others
Phase 1
11 of 198
none open now
Registered
153rd of 198
by date

Among the 198 studies in COVID-19 with a site in Mexico, this one is the 143rd largest by enrollment of the 151 interventional ones that give a count, is one of 57 that started in 2021, is one of 11 in phase 1, and was the 153rd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 198 studies in COVID-19 with a site in Mexico are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in COVID-19 with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to determine both the magnitude and duration of viral load (copies/mL) reduction after a single dose of OPN-019. The variability associated with viral counts will be utilized to inform the study design of future studies.

Read the detailed description

A randomized, single dose, adaptive design, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. Patients will be required to have a score ≤ 2 on the WHO ordinal scale for clinical improvement (Covid-19 Therapeutic Trial Synopsis; Feb 18, 2020). Those meeting the inclusion criteria will be randomized to 1 of 2 arms: OPN-019 (2 sprays per nostril) or SOC. Once randomized, subjects will have baseline nasal and oropharyngeal swabs performed for qRT-PCR viral load and infectious viral particle assessment. The subject will then be administered the study medication. Subsequent nasal and oropharyngeal swabs will be taken at 1 hour, 3 hours, 6 hours, 8 hours, 12 hours, and 24 hours. Cohorts of 10 subjects will be randomized into the study and the results from those subjects will be evaluated to determine if changes in the inclusion criteria or study assessments are required.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. men or women aged 18 years and older at Visit 1 (Baseline/Screening)
  2. women of must have a negative urine pregnancy test at Visit 1 (Baseline/Screening)
  3. must be confirmed positive for SARS-CoV-2 with RT-PCR testing of a nasal swab taken within 72 hours prior to randomization (first dose of study drug)
  4. must have a score ≤ 2 on the WHO ordinal scale for clinical improvement
  5. subject must be willing to refrain from any other intranasal instillations (e.g., medications, saline, etc.) for 24 hours after study medication dosing
  6. must be capable, in the opinion of the investigator, of providing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. women who are pregnant or lactating
  2. hospitalized subjects or subjects requiring nursing care for COVID-19
  3. currently has one of the clinical signs suggestive of moderate-to-severe COVID-19 illness:

    1. O2 saturation of ≤ 93% on room air at sea level
    2. Heart rate ≥ 90 beats per minute (after seated for 5 min)
    3. Respiratory rate ≥ 20 breaths per minute
  4. receiving respiratory support (including any form of oxygen therapy)
  5. history of hypothyroidism, goiter, hyperthyroidism, thyroid tumor, thyroid disease
  6. currently taking medications that contain iodine or currently taking lithium
  7. receiving any other drug
  8. has an allergy, , or to povidone iodine
  9. has an allergy or hypersensitivity to any in study medication
  10. any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    400 mg OPN-019

    Drug: OPN-019

  • No intervention
    Standard of Care (SOC)

Interventions

  • DrugOPN-019

    400 mg OPN-019, 2 sprays per nostril (one dose)

06

What researchers measure

Primary outcomes

  1. Change in nasal viral load over multiple time points

    Change in nasal viral load (copies/mL) over multiple time points as measured by qRT-PCR testing of nasal swabs.

    Time frame: Baseline, 1 Hour, 3 Hours, 6 Hours, 8 Hours, 12 Hours, 24 Hours post dosing/randomization

Secondary outcomes

  1. Cumulative viral load over 6, 8, and 12-hour periods in oropharyngeal swab

    Compare cumulative viral load (copies/mL) (total) over 6, 8, and 12-hour periods in oropharyngeal swab measured by qRT-PCR

    Time frame: 6 Hours, 8 Hours, 12 Hours post Dosing/Randomization

  2. Cumulative amount of Nasal Swab infectious viral particles

    Compare cumulative amount of infectious viral particles (copies/mL) between OPN-019 dosed subjects versus SOC control group in nasal swab

    Time frame: Baseline, 24 Hours post dosing/randomization

  3. Number of subjects with viral load of <10^6 copies/mL

    Compare the number of subjects who reach a viral load (copies/ml) of \<10\^6

    Time frame: Baseline, 24 Hours post dosing/randomization

  4. Maximum log reduction in viral load

    Compare maximum log reduction in viral load (copies/ml) by qRT-PCR

    Time frame: Baseline, 24 Hours post dosing/randomization

  5. Time Comparison-subject virus-free or has viral load of <10^6 copies/ml

    Time over which subject is virus-free or has viral load (copies/mL) of \<10\^6 , both as measured by qRT-PCR

    Time frame: Baseline, 24 Hours post dosing/randomization

  6. Log viral reduction assessment in subgroups-baseline viral load

    Assess log viral reduction in subgroups by baseline viral load (copies/mL)

    Time frame: Baseline, 24 Hours post dosing/randomization

Other outcomes

  1. Evaluation of Safety by recording the severity of spontaneously reported adverse events (AEs)

    Assessment of safety by measuring severity of spontaneously reported AEs using scale with 1=mild, 2=moderate, 3=severe

    Time frame: Baseline, 24 Hours post dosing/randomization

  2. Evaluation of Safety measuring vital signs- Blood Pressure

    Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

    Time frame: Baseline, 24 Hours post dosing/randomization

  3. Evaluation of Safety measuring vital signs- Pulse

    Measure pulse in beats per minute (bpm)

    Time frame: Baseline, 24 Hours post dosing/randomization

  4. Evaluation of Safety measuring vital signs- Temperature

    Measure temperature in °Fahrenheit (°F)

    Time frame: Baseline, 24 Hours post dosing/randomization

  5. Evaluation of Safety measuring vital signs- Respiratory Rate

    Measure Respiratory Rate in breaths per minute

    Time frame: Baseline, 24 Hours post dosing/randomization

  6. Evaluation of Safety - Monitoring Concomitant Medication Usage

    Assessment for safety from the collection of information for concomitant medications usage

    Time frame: Baseline, 24 Hours post dosing/randomization

  7. Evaluation of Safety - Study Drug Tolerability

    Study Medication Tolerability Questionnaire will be completed by subjects rate the levels of nasal discomfort and unpleasant taste associated with study medication use; study specific measure. The Study Medication Tolerability Questionnaire is administered verbally by a study staff member to the subject. This 11-item score is rated on a 0-100 scale, 0 being "dislike it an extreme amount", and 100 being "like it an extreme amount"

    Time frame: 1 Hour Post Dose

07

Study locations

1 site
  • Fundacion Santos y de la Garza Evia, I.B.P
    Monterrey, N.l. 64710, Mexico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Nov 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Sep 5, 2021
StartActual
Sep 1, 2021
Primary completionActual
Nov 30, 2021
CompletionActual
Nov 30, 2021
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05035576
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
Sep 5, 2021
Start date
Sep 1, 2021
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Last update
May 2, 2022

Study contacts

Jennifer Carothers
study director · OptiNose US
John Messina
study chair · OptiNose US

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion